Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
1.
Arthritis Care Res (Hoboken) ; 76(2): 304-309, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37522281

RESUMO

OBJECTIVE: Transparency of disclosure in publication is necessary for readers to be aware of any potential conflicts of interest (PCOIs). Past studies of accuracy of disclosure in rheumatology journals have focused exclusively on clinical practice guidelines and not research works. We assessed discrepancy in reporting PCOIs in clinically oriented manuscripts published in the three top-ranked (by impact factor) US-based general rheumatology journals. METHODS: We reviewed disclosures provided by first, second, and last authors of 50 published clinically oriented articles in each of the three top-ranked general US rheumatology journals. For each author, we extracted payment reports from the Open Payments Database (OPD) related to consulting fees, honoraria, and speaker or faculty compensation. We defined a PCOI as a payment received from a company with an ongoing clinical trial or a medication on the market related to the manuscript's subject matter within the 36 months before the online publication date. We additionally analyzed each author individually to determine whether their reported disclosures matched PCOIs from the OPD. RESULTS: Of 150 articles analyzed, 101 included authors with PCOIs. Ninety-two of these 101 publications (92%) contained inaccurate (non- or under-) disclosures. Among 135 authors with PCOIs, 118 reported inaccurately (87%). All 14 articles that published clinical trial results (and all 23 of their qualifying authors) had disclosure inaccuracies. CONCLUSION: Inaccurate financial disclosure by authors remains an issue in clinically oriented research studies reported in top rheumatology journals. Improved community education and firmer expectations would permit readers to better assess any possible impact of PCOIs on publications.


Assuntos
Publicações Periódicas como Assunto , Reumatologia , Humanos , Revelação , Conflito de Interesses , Bases de Dados Factuais
3.
Arthritis rheumatol. (Malden. Online) ; 72(6): [879­895], June 2020.
Artigo em Inglês | BIGG | ID: biblio-1117200

RESUMO

To provide guidance for the management of gout, including indications for and optimal use of urate- lowering therapy (ULT), treatment of gout ares, and lifestyle and other medication recommendation Fifty- seven population, intervention, comparator, and outcomes questions were developed, followed by a systematic literature review, including network meta- analyses with ratings of the available evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and patient input. A group consensus process was used to compose the nal recommendations and grade their strength as strong or conditional.Results. Forty- two recommendations (including 16 strong recommendations) were generated. Strong recommen-dations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout ares; allopurinol as the preferred rst- line ULT, including for those with moderate- to- severe chronic kidney disease (CKD; stage >3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat (<40 mg/day); and a treat- to- target management strategy with ULT dose titration guided by serial serum urate (SU) measurements, with an SU target of <6 mg/dl. When initiating ULT, concomitant antiinammatory prophylaxis therapy for a duration of at least 3­6 months was strongly recommended. For management of gout ares, colchicine, nonsteroidal antiinammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended.Conclusion. Using GRADE methodology and informed by a consensus process based on evidence from the current literature and patient preferences, this guideline provides direction for clinicians and patients making decisions on the management of gout.


Assuntos
Humanos , Ácido Úrico , Anti-Inflamatórios não Esteroides/uso terapêutico , Alopurinol/uso terapêutico , Febuxostat/uso terapêutico , Gota/complicações , Gota/prevenção & controle , Gota/terapia
4.
Arthritis Rheumatol ; 72(6): 879-895, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32390306

RESUMO

OBJECTIVE: To provide guidance for the management of gout, including indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations. METHODS: Fifty-seven population, intervention, comparator, and outcomes questions were developed, followed by a systematic literature review, including network meta-analyses with ratings of the available evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and patient input. A group consensus process was used to compose the final recommendations and grade their strength as strong or conditional. RESULTS: Forty-two recommendations (including 16 strong recommendations) were generated. Strong recommendations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares; allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease (CKD; stage >3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat (<40 mg/day); and a treat-to-target management strategy with ULT dose titration guided by serial serum urate (SU) measurements, with an SU target of <6 mg/dl. When initiating ULT, concomitant antiinflammatory prophylaxis therapy for a duration of at least 3-6 months was strongly recommended. For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended. CONCLUSION: Using GRADE methodology and informed by a consensus process based on evidence from the current literature and patient preferences, this guideline provides direction for clinicians and patients making decisions on the management of gout.


Assuntos
Supressores da Gota/normas , Gota/tratamento farmacológico , Reumatologia/normas , Alopurinol/normas , Anti-Inflamatórios não Esteroides/normas , Colchicina/normas , Febuxostat/normas , Humanos , Estados Unidos
5.
Arthritis Care Res (Hoboken) ; 72(6): 744-760, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32391934

RESUMO

OBJECTIVE: To provide guidance for the management of gout, including indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations. METHODS: Fifty-seven population, intervention, comparator, and outcomes questions were developed, followed by a systematic literature review, including network meta-analyses with ratings of the available evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and patient input. A group consensus process was used to compose the final recommendations and grade their strength as strong or conditional. RESULTS: Forty-two recommendations (including 16 strong recommendations) were generated. Strong recommendations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares; allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease (CKD; stage >3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat (<40 mg/day); and a treat-to-target management strategy with ULT dose titration guided by serial serum urate (SU) measurements, with an SU target of <6 mg/dl. When initiating ULT, concomitant antiinflammatory prophylaxis therapy for a duration of at least 3-6 months was strongly recommended. For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended. CONCLUSION: Using GRADE methodology and informed by a consensus process based on evidence from the current literature and patient preferences, this guideline provides direction for clinicians and patients making decisions on the management of gout.


Assuntos
Gota/terapia , Uricosúricos/administração & dosagem , Gerenciamento Clínico , Estilo de Vida Saudável , Humanos , Exacerbação dos Sintomas
7.
ACR Open Rheumatol ; 1(6): 343-344, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31777811
9.
Curr Opin Rheumatol ; 31(2): 118-124, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30601229

RESUMO

PURPOSE OF REVIEW: Gout is associated with the risk of cardiovascular morbidity and mortality, but the biological relationship between the two remains uncertain. The demonstration of reduction of cardiovascular risk with appropriate gout treatment would argue for a causal role for gout in cardiovascular disease. We reviewed recent studies that address the relationship between gout and cardiovascular disease. RECENT FINDINGS: Studies are conflicting; some show that lowering serum uric acid levels leads to better cardiovascular outcomes, whereas others show no such benefit. Inconsistencies in study design may contribute to these variations in outcome. Additionally, different gout treatment strategies may affect cardiovascular outcomes differently. SUMMARY: Despite an abundance of data generated in the last 5 years, it remains unclear whether treating gout with urate-lowering therapy provides a cardiovascular benefit. Additionally, further studies are needed to clarify whether different urate-lowering drugs confer different cardiovascular risks or benefits. Nonurate-lowering agents used for gout or commonly used in gout patients, such as colchicine and statins, may also improve cardiovascular outcomes in this population.


Assuntos
Doenças Cardiovasculares/etiologia , Colchicina/uso terapêutico , Gota/complicações , Biomarcadores/sangue , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Saúde Global , Gota/tratamento farmacológico , Supressores da Gota/uso terapêutico , Humanos , Morbidade/tendências , Taxa de Sobrevida/tendências , Ácido Úrico/sangue
12.
Conn Med ; 81(5): 285-289, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-29738130

RESUMO

Human immunodeficiency virus (HIV) infection can result in several autoimmune illnesses, including psoriasis, psoriatic arthritis (PsA), and polyarteritis nodosa (PAN). We describe a patient who presented with PsA refractory to both synthetic and biologic disease-modifying antirheumatic drugs (DMARDs), who then developed PAN while on antitumor necrosis factor (TNF) therapy. The onset ofvasculitic disease led to the discovery of the HIV infection, and manifestations of both PsA and PAN remitted with the introduction of highly active antiretroviral therapy. To our knowledge, this is the first casewhere both PsA and PAN developed in an HIV-positive patient. Our review focuses on the pathogenesis, presentation, and treatment of HIV related psoriasis, PsA, and PAN. This unusual case underscores the need to remain vigilant for underlying HIV infection in immunosuppressed patients, and serves as a reminder ofthe unusual autoimmune manifestations the virus can provoke.


Assuntos
Terapia Antirretroviral de Alta Atividade , Antirreumáticos/uso terapêutico , Artrite Psoriásica/complicações , Infecções por HIV/complicações , Hospedeiro Imunocomprometido , Poliarterite Nodosa/complicações , Adulto , Terapia Antirretroviral de Alta Atividade/métodos , Artrite Psoriásica/diagnóstico , Artrite Psoriásica/tratamento farmacológico , Quimioterapia Combinada , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Humanos , Masculino , Poliarterite Nodosa/diagnóstico , Poliarterite Nodosa/tratamento farmacológico , Prognóstico , Resultado do Tratamento
14.
Clin Rheumatol ; 35(7): 1713-8, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27044430

RESUMO

Antinuclear antibody (ANA) test results frequently affect the course of patients' evaluations, diagnosis, and treatment, but different laboratory centers may yield conflicting results. This study investigated the degree of agreement between laboratory results in a group of subjects who had ANA testing performed at two commercial laboratories. This was a chart review study, in which all ANA tests ordered by the authors from one commercial laboratory over a 4-year period were queried. Corresponding patient charts were reviewed, and if ANA testing had also been performed at the second commercial laboratory, subjects were entered into the study. The primary measurement was agreement between paired ANA results, and we performed sensitivity analysis using varying criteria defining agreement (criteria A to criteria D [strictest to most lenient definition of agreement]). Other data captured included relevant data obtained through the course of evaluation (e.g., presenting complaints, exam findings, other laboratory data) and final diagnoses. Of 101 paired ANA tests, there was 18 % agreement according to the strictest criteria and 42 % according to the most lenient. Of the seven subjects with ANA-associated rheumatic disease, none of the paired tests were in agreement according to criteria A (two agreed according to criteria D). Our findings demonstrate poor agreement between paired ANA tests performed at two commercial laboratories. The low level of agreement may have far-reaching clinical implications. Specifically, this finding calls into question the reliability of ANA testing as it is currently performed and suggests that results may in part depend upon the laboratory center to which patients are referred.


Assuntos
Anticorpos Antinucleares/sangue , Laboratórios/normas , Programas de Rastreamento/métodos , Doenças Reumáticas/diagnóstico , Técnica Indireta de Fluorescência para Anticorpo , Humanos , Reprodutibilidade dos Testes
15.
Curr Rheumatol Rep ; 17(3): 13, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25740704

RESUMO

Across the globe, both gout and hyperuricemia have become increasingly common over the last few decades. The burden of gouty disease is made heavier by its association with several comorbid conditions, including hypertension, cardiovascular disease, and chronic kidney disease. Accruing evidence from prospective studies suggests that gout is an independent risk factor for developing cardiovascular disease and for higher cardiovascular mortality. While asymptomatic hyperuricemia does not seem to be an independent risk factor for cardiovascular disease, increasing data implicates hyperuricemia as a risk factor for developing incidental hypertension. Important questions that remain unanswered include whether addressing asymptomatic hyperuricemia forestalls the onset of hypertension, and whether treating gout with urate-lowering agents improves cardiovascular outcomes. This article reviews the most recent data regarding the relationship between hyperuricemia, gout, hypertension, and cardiovascular disease, as well as emerging evidence as to whether treatment of hyperuricemia and gout improves cardiovascular outcomes.


Assuntos
Doenças Cardiovasculares/etiologia , Gota/complicações , Hiperuricemia/complicações , Humanos , Fatores de Risco
16.
Arthritis Res Ther ; 16(3): 112, 2014 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-25142440

RESUMO

Pegloticase is a powerful but underutilized weapon in the rheumatologist's armamentarium. The drug's immunogenicity leads to neutralizing antibody formation and rapid loss of efficacy in roughly one-half of all patients, which remains an impediment to broader use. New data, however, suggest that drug survival might improve with concomitant immunosuppressive agent (s), which merits further study. Efficacy appears to be unchanged when pegloticase is infused at 3-week (rather than 2-week) intervals. Stretching the time between infusions may also improve patient adherence and allow for earlier identification of transient responders.


Assuntos
Supressores da Gota/administração & dosagem , Supressores da Gota/imunologia , Gota/tratamento farmacológico , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/uso terapêutico , Urato Oxidase/administração & dosagem , Urato Oxidase/imunologia , Urato Oxidase/uso terapêutico , Feminino , Humanos , Masculino
17.
Vascular ; 22(4): 313-6, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24000082

RESUMO

Thromboangiitis obliterans, or Buerger's disease, is a non-atherosclerotic, segmental, inflammatory disease affecting the small- and medium-sized vessels of the distal extremities. Other than discontinuation of tobacco, there is no standard-of-care treatment. Although two randomized trials have demonstrated a role for intravenous iloprost, no oral drug has yet been demonstrated to be effective in treating thromboangiitis obliterans. We present the first three reported cases of thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors, followed by a discussion of the rationale for the use of these agents in thromboangiitis obliterans.


Assuntos
Mãos/irrigação sanguínea , Inibidores da Fosfodiesterase 5/uso terapêutico , Tromboangiite Obliterante/tratamento farmacológico , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Tromboangiite Obliterante/diagnóstico , Tromboangiite Obliterante/enzimologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA